非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识  

An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos(t)ide analogues

作　　者：中华医学会肝病学分会肝炎学组 中华肝脏病杂志 窦晓光[2] 万谟彬[3] The Hepatitis Group,Chinese Society of Hepatology;Chinese Medical Association,Chinese Journal of Hepatology

机构地区：[1]不详 [2]中国医科大学附属盛京医院感染科,沈阳110022 [3]上海长海医院感染科,200433

出　　处：《中华肝脏病杂志》2019年第5期343-346,共4页Chinese Journal of Hepatology

摘　　要：口服核苷(酸)类似物(NAs)抗病毒治疗是治疗慢性乙型肝炎(CHB)重要和有效的方法之一。从抗病毒作用强弱及耐药方面考虑,国内外指南将NAs类药物分为一线和非一线用药。《非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识》主要针对目前正在使用非一线NAs类药物且有效的患者,如何规范地调整为一线NAs类药物,并强化CHB初始抗病毒治疗必须选择一线NAs类药物,使患者既可以获得更好的抗病毒疗效,提高患者的依从性,同时又可避免药物严重不良反应的发生。Oral nucleos(t)ide analogues(NAs)is one of the main and efficient way for the treatment of chronic hepatitis B(CHB).Considering the antiviral potency and drug resistance of domestic and foreign guidelines,NAs are divided into first-line and non-first-line drugs."An Expert Consensus for the Adjustment of Treatment Strategies in Patients with Chronic Hepatitis B Treated with Non-first-line Nucleos(t)ide Analogues,"is mainly aimed at those patients who are currently using non-first-line NAs drugs.In addition,how to standardize the adjustment to first-line NAs drugs of choice,which can strengthen the effectiveness of initial antiviral treatment to obtain better antiviral efficacy,and improve patient compliance,coinciding with the avoidance of occurrence of serious drug adverse reactions in patients with CHB is presented.

关 键 词：核苷(酸)类似物 乙型肝炎 慢性 经治 治疗策略 共识 

分 类 号：R512.62[医药卫生—内科学]